FrancophonIA/ELRC3.0 huggingface dataset:
English: 7.5 mg/kg intravenous 30-90 mins
Danish: 7,5 mg/kg intravenøs 30-90 min
English: In patients with moderate renal impairment at baseline, a dose reduction to 75% for a starting dose of 1250 mg/m2 is recommended.
Danish: Til patienter med moderat nedsat nyrefunktion ved baseline anbefales det at reducere dosis til 75 % af en initialdosis på 1.250 mg/m2.
English: Severe skin reactions: Ecansya can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Danish: Ecansya kan inducere alvorlige hudreaktioner såsom Stevens-Johnsons syndrom og toksisk epidermal nekrolyse.
English: - Stomatitis: if you have pain, redness, swelling or sores in your mouth and/or throat.
Danish: - Mundbetændelse: hvis du har smerter, rødme, hævelse eller sår i din mund og/eller hals.
English: Data from a randomised clinical study (Souglakos et al, 2012) comparing FOLFIRI + bevacizumab with XELIRI + bevacizumab showed no significant differences in PFS or OS between treatments.
Danish: Data fra et randomiseret klinisk studie (Souglakos et al, 2012), som sammenlignede FOLFIRI + bevacizumab med XELIRI + bevacizumab, viste ingen signifikant forskel i progressionsfri overlevelse og samlet overlevelse mellem de to behandlinger.
English: Number of 150 mg tablets, 300 mg tablets and/or 500 mg tablets per administration (each administration to be given morning and evening)
Danish: Antal 150 mg tabletter og/eller 300 mg tabletter og/eller 500 mg tabletter pr. dosering (hver dosering skal gives morgen og aften)
English: - as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Danish: - som monoterapi til behandling af patienter med lokal fremskreden eller metastatisk brystkræft efter svigt af taxaner og et kemoterapiregime indeholdende et antracyklin eller hos hvem antracyklin-behandling ikke er indiceret.
English: Table 8 Key efficacy results for AIO KRK study XELOX + bevacizumab
Danish: Tabel 8 Nøgleresultater for effekt fra AIO KRK-studiet XELOX + bevacizumab
English: The elimination half-life (t1/2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively.
Danish: Eliminationshalveringstiden (t½, timer) for capecitabin, 5'-DFCR, 5'-DFUR, 5-FU og FBAL var 0,85, 1,11, 0,66, 0,76 og 3,23.
English: Hypo- or hypercalcaemia has been reported during capecitabine treatment.
Danish: Der er rapporteret om hypo- og hyperkalcæmi under behandling med capecitabin.
English: QT prolongation (rare), Torsade de pointes (rare), Bradycardia (rare), Vasospasm (rare)
Danish: Ventrikelflimmer (sjælden), QT-forlængelse (sjælden), Torsades de pointes (sjælden), Bradykardi (sjælden), Karspasme (sjælden)
English: Rigors, Body temperature increased ** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysaesthesia syndrome can eventually lead to loss of fingerprints (see section 4.4.)
Danish: ** Baseret på erfaringer efter markedsføring kan vedvarende eller svært palmar-plantar erytrodysæstesi syndrom i sidste ende forårsage, at fingeraftrykket forsvinder (se pkt.
English: + For each term, the frequency count was based on ADRs of all grades.
Danish: Kontusion + For hver term er hyppigheden baseret på bivirkninger af alle grader.
English: Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone).
Danish: Den mediane overlevelse var 442 dage (docetaxel + capecitabin) vs. 352 dage (docetaxel alene).
English: You must inform your doctor if you know that you have an allergy or over-reaction to this medicine, - if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines, such as fluorouracil), - if you are pregnant or breast-feeding, - if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia), - if you have severe liver or kidney problems, - if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD) - if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.
Danish: Du skal fortælle din læge, hvis du er overfølsom over for eller reagerer kraftigt på dette lægemiddel - hvis du tidligere har haft alvorlige bivirkninger ved fluorpyrimidin-behandling (en gruppe af kræftlægemidler som fluorouracil) - hvis du er gravid eller ammer - hvis du har meget få hvide blodlegemer eller blodplader i blodet (leukopeni, neutropeni eller trombocytopeni) - hvis du har svære lever eller nyreproblemer - hvis du ved, at du ikke har nogen aktivitet af enzymet dihydropyrimidindehydrogenase (DPD), - hvis du bliver behandlet på nuværende tidspunkt eller inden for de sidste 4 uger har været behandlet med brivudin som en del af herpes zosterbehandling (skoldkopper eller helvedesild).
English: Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection, Rhinitis, Influenza,
Danish: Herpes zoster, Urinvejsinfektion, Oral candidiasis, Øvre luftvejsinfektion, Rhinitis, Influenza,
English: There is no relevant use of capecitabine in the paediatric population in the indications colon, colorectal, gastric and breast cancer.
Danish: Det er ikke relevant at anvende capecitabin hos den pædiatriske population til indikationerne kolonkræft, kolorektalkræft, ventrikelkræft og brystkræft.
English: Paraesthesia, Dysaesthesia, Peripheral neuropathy, Peripheral sensory neuropathy, Dysgeusia, Headache
Danish: Paræstesi, Dysæstesi, Perifer neuropati, Perifer sensorisk neuropati, Dysgeusi, Hovedpine
English: Patients ≥ 60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients < 60 years of age.
Danish: Der var flere patienter  60 år, som behandledes med capecitabin plus docetaxel, som måtte stoppe behandlingen tidligt på grund af bivirkninger, sammenlignet med patienter < 60 år.
English: Coumarin-derivative anticoagulants: altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
Danish: Der er rapporteret om ændrede koagulationsparametre og/eller ændret blødning hos patienter som tog capecitabin sammen med antikoagulantia af coumarintypen såsom warfarin og phenprocoumon.
English: - metastatic colorectal cancer (see section 5.1).
Danish: - metastatisk kolorektalkræft (se pkt.
English: LIST OF EXCIPIENTS Also contains lactose.
Danish: LISTE OVER HJÆLPESTOFFER Indeholder også vandfri lactose.
English: Radiotherapy: the MTD of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.
Danish: Stråleterapi MTD for capecitabin alene ved anvendelse af det intermitterende regime er 3.000 mg/m2 pr. dag, hvorimod MTD er 2.000 mg/m2 pr. dag, når capecitabin kombineres med stråleterapi ved kolorektalkræft, enten ved anvendelse af en kontinuerlig behandling eller anvendt dagligt fra mandag til fredag under en seks ugers serie med stråleterapi.
English: Survival was superior in the capecitabine + docetaxel combination arm (p=0.0126).
Danish: Overlevelsen var bedre i kombinationsarmen med capecitabin + docetaxel (p = 0,0126).
English: Colon and colorectal cancer:
Danish: Kolon- og kolorektalkræft:
English: Ecansya is indicated for the treatment of: - for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer (see section 5.1).
Danish: Ecansya er indiceret som behandling af: - for den adjuverende behandling af patienter, som er opereret for stadium III (Dukes stadium C)
English: Dose limiting toxicities
Danish: Dosisbegrænsende toksicitet
English: Neutropenia, Anaemia
Danish: Neutropeni, Anæmi
English: The rate of withdrawal due to adverse events was higher in the XELOX combination therapy arm (21%) as compared with that of the 5-FU/LV monotherapy arm (9%) in the ITT population.
Danish: Hos ITT-populationen var raten for behandlingsophør på grund af bivirkninger højere i XELOX kombinationsterapi-armen (21 %) sammenlignet med den i 5-FU/LV monoterapi-armen (9 %).
English: Diarrhoea.
Danish: Diarré
English: Advanced gastric cancer:
Danish: Fremskreden ventrikelkræft:
English: During a treatment cycle for those toxicities considered by the treating physician not to be related to capecitabine, capecitabine should be continued and the dose of the other medicinal product should be adjusted according to the appropriate Prescribing Information.
Danish: For de toksiske virkninger, der af den behandlende læge under en behandlingsserie ikke anses for at være relateret til capecitabin, bør behandlingen med capecitabin fortsætte, og dosis af det andet lægemiddel bør justeres i henhold til det pågældende produktresumé.
English: Dihydropyrimidine dehydrogenase (DPD) deficiency: Rarely, unexpected, severe toxicity (e.g. stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-FU has been attributed to a deficiency of DPD activity.
Danish: Sjælden, uventet, svær toksicitet (fx stomatitis, diarré, slimhindeinflammation, neutropeni og neurotoksicitet) i forbindelse med 5-FU er tilskrevet manglende DPD-aktivitet.
English: However this was associated with an increased incidence of gastrointestinal toxicity and neutropenia during first-line treatment with XELIRI (26% and 11% for XELIRI and first line capecitabine respectively).
Danish: 1. linjebehandling med XELIRI var dog forbundet med en øget incidens af gastrointestinal toksicitet og neutropeni (26 % og 11 % for henholdsvis XELIRI og 1. linjebehandling med capecitabin).
English: For patients 60 years of age or more, a starting dose reduction of capecitabine to 75% (950 mg/m2 twice daily) is recommended.
Danish: Til patienter på 60 år og derover anbefales det at reducere initialdosis af capecitabin til 75 % af vanlig initialdosis (950 mg/m2 to gange dagligt).
English: Patients taking coumarinderivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted accordingly.
Danish: Patienter som tager antikoagulantia af coumarintypen sammen med capecitabin skal kontrolleres regelmæssigt mht. ændringer i deres koagulationsparametre (PT eller INR), og antikoagulansdosis skal om nødvendigt justeres.
English: Uncommon ADRs reported for capecitabine in combination therapy are consistent with the ADRs reported for capecitabine monotherapy or reported for monotherapy with the combination medicinal product (in literature and/or respective summary of product characteristics).
Danish: Ikke almindelige bivirkninger, der er rapporteret ved behandling med capecitabin i kombination med andre lægemidler, er i overensstemmelse med de bivirkningsrapporteringer, der er rapporteret for capecitabin-monoterapi eller for monoterapi med kombinationslægemidlet (i litteratur og/eller respektive produktresuméer).
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Danish: Du kan finde yderligere information om Ecansya på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
English: In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.
Danish: Hvis du bruger blodfortyndende medicin (antikoagulantia) af coumarintypen (indeholdende f.eks.phenprocoumon) kan det blive nødvendigt, at din læge ændrer dosis af denne medicin, hvis behandlingen med capecitabin stopper.
English: Caution must be exercised in patients with history of significant cardiac disease, arrhythmias and angina pectoris (see section 4.8).
Danish: Der skal iagttages forsigtighed hos patienter, som har signifikant hjertesygdom, arytmier og angina pectoris i anamnesen (se pkt.
English: Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described.
Danish: Der er beskrevet en klinisk signifikant interaktion mellem brivudin og fluorpyrimidiner (f.eks. capecitabin, 5-FU, tegafur), som et resultat af brivudins hæmning af dihydropyrimidindehydrogenase.
English: Myalgia, Arthralgia, Pain in extremity
Danish: Myalgi, Artralgi, Smerter i ekstremiteterne
English: NCIC CTC grade 2 diarrhoea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhoea as an increase of 7 to 9 stools/day or incontinence and malabsorption.
Danish: NCIC CTC grad 2 diarré defineres som en øgning til 4 til 6 afføringer/dag eller natlige afføringer, grad 3 diarré som som en øgning til 7 til 9 afføringer/dag eller inkontinens og malabsorption, og grad 4 diarré som en øgning til flere end 10 afføringer/dag eller stærkt blodig diarré eller behov for parenteral støttebehandling.
English: Combination therapy in adjuvant colon cancer
Danish: Adjuverende kombinationsterapi ved kolonkræft
English: In the case of colorectal tumours, 5-FU generation appears to be in large part localised in tumour stromal cells.
Danish: For så vidt angår kolorektale tumorer synes dannelsen af 5-FU hovedsageligt at være lokaliseret til stromale tumorceller.
English: DPD deficiency: if you have a known DPD deficiency, you are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by Ecansya (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity).
Danish: - DPD-mangel: hvis du ved, at du har DPD-mangel, har du en øget risiko for akut tidlig indtræden af bivirkninger og svære, livstruende eller dødelige bivirkninger forårsaget af Ecansya (f.eks. mundbetændelse, betændelseslignende reaktion (inflammation) i slimhinder, diarré, neutropeni og neurotoksicitet)
English: The enzyme involved in the final conversion to 5-FU, thymidine phosphorylase (ThyPase), is found in tumour tissues, but also in normal tissues, albeit usually at lower levels.
Danish: Enzymet thymidinfosforylase (ThyPase), som er involveret i den endelige omdannelse til 5-FU, findes i tumorvæv, men også i normalt væv, om end i lavere koncentrationer.
English: The 3 year DFS rate was 71% for XELOX versus 67% for 5-FU/LV.
Danish: Raten for 3 års sygdomsfri overlevelse var 71 % for XELOX versus 67 % for 5FU/LV.
English: At the dose of 1250 mg/m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in µg/ml) for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively.
Danish: Efter en dosis på 1250 mg/m2 efter indtagelse af føde var peak-plasmakoncentrationerne på dag 14 (Cmax, g/ml) for capecitabin, 5'-DFCR, 5'-DFUR, 5-FU og FBAL 4,67; 3,05; 12,1; 0,95 og 5,46.
English: Cardiac arrhythmias (including ventricular fibrillation, torsade de pointes, and bradycardia), angina pectoris, myocardial infarction, heart failure and cardiomyopathy have been reported in patients receiving capecitabine.
Danish: Der er rapporteret om kardiale arytmier (herunder ventrikelflimren, torsades de pointes og bradykardi), angina pectoris, myokardieinfarkt, hjerteinsufficiens og kardiomyopati hos patienter, som får capecitabin.
English: (see section 4.4), - During pregnancy and lactation, - In patients with severe leukopenia, neutropenia, or thrombocytopenia, - In patients with severe hepatic impairment, - In patients with severe renal impairment (creatinine clearance below 30 ml/min), - Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug interaction),
Danish: 4.4), - Graviditet og amning, - Patienter med svær leukopeni, neutropeni eller trombocytopeni, - Patienter med svær leverinsufficiens, - Patienter med svær nyreinsufficiens (creatininclearance under 30 ml/min), - Nylig eller samtidig behandling med brivudin (se pkt.
English: Within each frequency grouping, ADRs are presented in order of decreasing seriousness.
Danish: Inden for hver enkelt frekvensgruppe er bivirkningerne opstillet efter, hvor alvorlige de er.
English: XELOX showed a trend towards superior OS with a HR of 0.87 (95% CI=[0.72; 1.05]; p=0.1486) which translates into a 13% reduction in risk of death.
Danish: XELOX viste en tendens til en bedre samlet overlevelse med en hazard ratio på 0,87 (95 % konfidensinterval = [0,72; 1,05], p = 0,1486), hvilket svarer til en reduktion i risikoen for dødsfald på 13 %.
English: Caution must be exercised in patients with central or peripheral nervous system disease, e.g. brain metastasis or neuropathy (see section 4.8).
Danish: Der skal iagttages forsigtighed hos patienter med sygdomme i centralnervesystemet eller i det perifere nervesystem, f.eks. hjernemetastaser eller neuropati (se pkt.
English: Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureidopropionic acid (FUPA).
Danish: Dihydropyrimidinase spalter pyrimidinringen til 5-fluoroureidopropionsyre (FUPA).
English: Premedication to maintain adequate hydration and anti-emesis according to the cisplatin summary of product characteristics should be started prior to cisplatin administration for patients receiving the capecitabine plus cisplatin combination.
Danish: Præmedicinering til opretholdelse af tilstrækkelig hydrering og antiemetisk behandling påbegyndes, i henhold til produktresumeet for cisplatin, før administration af cisplatin, hos de patienter, som får kombinationsbehandling med capecitabin og cisplatin.
English: See section 5.1 for details of major studies, including study designs and major efficacy results.
Danish: Detaljeret beskrivelse af de største forsøg inklusive forsøgsdesign og overordnede effektresultater findes i pkt.
English: The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/embolism.
Danish: De mest almindelige rapporterede og/eller klinisk relevante behandlingsrelaterede bivirkninger var gastrointestinale symptomer (specielt diarré, kvalme, opkastning, mavesmerter og stomatitis), håndog fodsyndrom (palmoplantar erytrodysæstesi), træthed, asteni, anoreksi, kardiotoksicitet, øget renal dysfunktion hos dem med præeksisterende kompromitteret nyrefunktion samt trombose/embolisme.
English: Oxaliplatin 130 mg/m intravenous 2 hr
Danish: Oxaliplatin 130 mg/m intravenøs 2 timer
English: The manifestations of acute overdose include nausea, vomiting, diarrhoea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression.
Danish: Symptomerne på akut overdosering omfatter kvalme, opkastning, diarré, mucositis, gastrointestinal irritation og blødning samt knoglemarvssuppression.
English: Hand-foot syndrome (also known as hand-foot skin reaction or palmar-plantar erythrodysesthesia or chemotherapy induced acral erythema).
Danish: Hånd- og fodsyndrom også kendt som hånd- og fodhudreaktion, palmoplantar erytrodysæstesi eller kemoterapiinduceret akralt erytem.
English: Median OS was 23.1 months for FOLFIRI, 17.6 months for mIFL (p=0.09), and 18.9 months for XELIRI (p=0.27).
Danish: Den mediane samlede overlevelse var 23,1 måneder for FOLFIRI, 17,6 måneder for mIFL (p = 0,09) og 18,9 måneder for XELIRI (p = 0,27).
English: Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
Danish: Influenzalignende symptomer, Feber, Infusionsrelateret reaktion, Reaktion på injektionsstedet, Smerter på infusionsstedet, Smerter på injektionsstedet
English: Colon, colorectal and advanced gastric cancer: meta-analysis A meta-analysis of six clinical trials (studies SO14695, SO14796, M66001, NO16966, NO16967, M17032) supports capecitabine replacing 5-FU in mono- and combination treatment in gastrointestinal cancer.
Danish: Kolonkræft, kolorektalkræft og fremskreden ventrikelkræft, metaanalyse En metaanalyse af seks kliniske forsøg (studie SO14695, SO14796, M66001, NO16966, NO16967 og M17032) støtter, at capecitabin kan erstatte 5-FU i mono- og kombinationsbehandling af gastrointestinal kræft.
English: In a randomised, controlled phase III study (CAIRO), the effect of using capecitabine at a starting dose of 1000 mg/m2 for 2 weeks every 3 weeks in combination with irinotecan for the first-line treatment of patients with metastatic colorectal cancer was studied.
Danish: I et randomiseret, kontrolleret fase III-studie (CAIRO) blev effekten af capecitabin ved anvendelse af en initialdosis på 1.000 mg/m2 i 2 uger hver 3. uge i kombination med irinotecan som 1. linjebehandling af patienter med metastatisk kolorektalkræft undersøgt.
English: Caution must be exercised in patients with pre-existing hypo- or hypercalcaemia (see section 4.8).
Danish: Der skal iagttages forsigtighed hos patienter med tidligere hypo- eller hyperkalcæmi (se pkt.
English: 604 patients were randomised to treatment with 5-FU and leucovorin (Mayo regimen: 20 mg/m2 leucovorin intravenous followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days).
Danish: 604 patienter randomiseredes til behandling med 5-FU og leucovirin (Mayo regime: 20 mg/m2 leucovirin intravenøs efterfulgt af en 5-FU bolus på 425 mg/m2 intravenøs på dag 1 til 5, hver 28. dag).
English: The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min at baseline) is increased compared to the overall population.
Danish: Incidensen af bivirkninger af sværhedsgrad 3 eller 4 er højere hos patienter med moderat nedsat nyrefunktion (creatininclearance 30 - 50 ml/min ved baseline), sammenlignet med den samlede population.
English: Insufficient safety and efficacy data are available in patients with hepatic impairment to provide a dose adjustment recommendation.
Danish: På grund af utilstrækkelige tilgængelige sikkerheds- og effektdata hos patienter med nedsat leverfunktion er der ingen anbefalet dosering.
English: Very rare side effects (may affect up to 1 in 10,000 people) include: - severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes)
Danish: Meget sjældne bivirkninger (kan påvirke op til 1 ud af 10.000 personer): - svære hudreaktioner såsom hududslæt, sårdannelse og blæredannelse, som kan give sår i munden, næsen, kønsorganer, hænder, fødder og øjne (røde og opsvulmede øjne).
English: The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see table 9).
Danish: Resultaterne indikerer, at XELOX er ækvivalent med FOLFOX-4 med hensyn til samlet overlevelse (se tabel 9).
English: The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see table 7).
Danish: Resultaterne indikerer, at XELOX er ækvivalent med FOLFOX-4 med hensyn til den samlede overlevelse (se tabel 7).
English: Premedication with an oral corticosteroid such as dexamethasone according to the docetaxel summary of product characteristics should be started prior to docetaxel administration for patients receiving the capecitabine plus docetaxel combination.
Danish: Præmedicinering med et oralt kortikosteroid, som f.eks. dexamethason, af patienter, som får en kombination af capecitabin og docetaxel, bør ifølge produktresumeet for docetaxel påbegyndes, før der gives docetaxel.